Arbutus Biopharma Corp (ABUS)
Arbutus Biopharma Corp operates in the Biotechnology industry of the Healthcare sector, headquartered in Warminster, PA, US. The stock last traded at $4.53, down 3.10% on the session, giving a market capitalisation of $893.9M. On trailing twelve-month figures it carries a trailing P/E of 5.72, a net margin of 84.2%. Its beta of 0.60 implies it has historically moved less than the broad market.
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma Corp is most often compared with the following Healthcare names: